Do you develop on GitHub? You can keep using GitHub but automatically sync your GitHub releases to SourceForge quickly and easily with this tool so your projects have a backup location, and get your project in front of SourceForge's nearly 20 million monthly users. It takes less than a minute. Get new users downloading your project releases today!
with the environment.
If I saw a chicken cross the road, I would just say, "Huh, a chicken!". But it could be a new species of chicken never before seen by "science" and i would think nothing of it. Just like seeing another lizard in the tropics. "Eew! a lizard!"
You are aware of the accidents ONLY because the news picked up on it. Accidents happen every day that aren't national or news worthy.
It would be interesting to see it there are the same number of Toyota accidents on average before, and since.
I can't remeber where, but I read that the first use of this would be for Cereal Boxes. They would use the moving images to attract peoples attention in the cereal aisle.
Can you imagine if this were implemented on every flat surface we encounter on a daily basis?
Posted
by
timothy
from the just-leave-it-on-a-few-years dept.
GeneralSoh writes "Delaying clamping the umbilical cord at birth may have far-reaching benefits for your baby, according to researchers at the University of South Florida's Center of Excellence for Aging and Brain Repair — and should be delayed for at least a few minutes longer after birth. This new recommendation published in the most recent Journal of Cellular and Molecular Medicine (14:3) notes that delaying clamping the umbilical cord allows more umbilical cord blood and crucial stem cells to transfer from mama to baby."
Increasing the number of times I spank the monkey a day isn't going to increase my chances of getting a girl into my basement. But I've lost count either way.
Posted
by
timothy
from the where-you-can-stick-it dept.
reverseengineer writes "The US Food and Drug Administration has given its first first approval for a therapeutic cancer vaccine. In a clinical trial 'involving 512 men, those who got Provenge (sipuleucel-T) had a median survival of 25.8 months after treatment, while those who got a placebo lived a median of 21.7 months. After three years, 32 percent of those who got Provenge were alive, compared with 23 percent of those who got the placebo. ... "The big story here is that this is the first proof of principle and proof that immunotherapy works in general in cancer, which I think is a huge observation," said Dr. Philip Kantoff, chief of solid tumor oncology at the Dana-Farber Cancer Institute in Boston and the lead investigator in Dendreon's largest clinical trial for the drug. "I think this is a very big thing and will lead to a lot more enthusiasm for the approach."'"